Across melanoma patient cohorts, exosomal PD-L1 levels consistently predicted inferior outcomes under ICIs, where higher EV PD-L1 abundance was linked to shorter overall survival and reduced therapeutic efficacy. This evidence concerns the gene CD274 and melanoma.